APVO
Income statement / Annual
Last year (2024), Aptevo Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Aptevo Therapeutics Inc.'s net income was -$24.13 M.
See Aptevo Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$3.11 M |
$12.29 M |
$4.31 M |
$0.00 |
$23.07 M |
$14.66 M |
$36.43 M |
$33.60 M |
| Cost of Revenue |
$352.00 K
|
$0.00
|
$0.00
|
$0.00
|
$17.85 M
|
$2.24 M
|
$11.21 M
|
$5.01 M
|
$24.18 M
|
$16.93 M
|
| Gross Profit |
-$352.00 K
|
$0.00
|
$3.11 M
|
$12.29 M
|
-$13.54 M
|
-$2.24 M
|
$11.85 M
|
$9.65 M
|
$12.25 M
|
$16.67 M
|
| Gross Profit Ratio |
0
|
0
|
1
|
1
|
-3.14
|
0
|
0.51
|
0.66
|
0.34
|
0.5
|
| Research and Development Expenses |
$14.38 M
|
$17.11 M
|
$17.88 M
|
$18.99 M
|
$17.85 M
|
$24.76 M
|
$35.39 M
|
$29.02 M
|
$29.52 M
|
$34.73 M
|
| General & Administrative Expenses |
$10.22 M
|
$11.77 M
|
$13.87 M
|
$14.70 M
|
$13.95 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.22 M
|
$11.77 M
|
$13.87 M
|
$14.70 M
|
$13.95 M
|
$13.96 M
|
$28.13 M
|
$34.58 M
|
$38.67 M
|
$43.04 M
|
| Other Expenses |
-$352.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$17.85 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$24.25 M
|
$28.88 M
|
$31.76 M
|
$33.69 M
|
$13.95 M
|
$38.73 M
|
$63.52 M
|
$63.60 M
|
$68.18 M
|
$77.77 M
|
| Cost And Expenses |
$24.60 M
|
$28.88 M
|
$31.76 M
|
$33.69 M
|
$31.80 M
|
$40.96 M
|
$74.73 M
|
$68.61 M
|
$92.37 M
|
$94.70 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$352.00 K
|
$567.00 K
|
$901.00 K
|
$1.14 M
|
$1.31 M
|
$2.24 M
|
$2.39 M
|
$2.30 M
|
$1.90 M
|
$2.91 M
|
| EBITDA |
-$23.78 M |
-$28.31 M |
-$27.74 M |
-$20.26 M |
-$26.19 M |
-$40.83 M |
-$49.28 M |
-$50.82 M |
-$64.40 M |
-$58.19 M |
| EBITDA Ratio |
0
|
0
|
-8.91
|
-1.65
|
-6.08
|
0
|
-2.14
|
-3.47
|
-1.77
|
-1.73
|
| Operating Income Ratio |
0
|
0
|
-9.2
|
-1.74
|
-6.38
|
0
|
-2.24
|
-3.68
|
-3.48
|
-1.82
|
| Total Other Income/Expenses Net |
$472.00 K
|
$10.23 M
|
$35.66 M
|
-$8.01 M
|
-$3.43 M
|
-$2.10 M
|
-$2.02 M
|
-$1.94 M
|
-$12.64 M
|
-$237.00 K
|
| Income Before Tax |
-$24.13 M
|
-$18.65 M
|
$7.01 M
|
-$29.41 M
|
-$30.92 M
|
-$43.06 M
|
-$53.69 M
|
-$55.89 M
|
-$127.76 M
|
-$61.34 M
|
| Income Before Tax Ratio |
0
|
0
|
2.25
|
-2.39
|
-7.18
|
0
|
-2.33
|
-3.81
|
-3.51
|
-1.83
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$23.30 M
|
-$15.34 M
|
-$2.02 M
|
| Net Income |
-$24.13 M
|
-$17.41 M
|
$8.03 M
|
-$28.46 M
|
-$17.75 M
|
-$44.70 M
|
-$53.69 M
|
$6.97 M
|
-$112.42 M
|
-$59.32 M
|
| Net Income Ratio |
0
|
0
|
2.58
|
-2.32
|
-4.12
|
0
|
-2.33
|
0.48
|
-3.09
|
-1.77
|
| EPS |
-1747.68 |
-46335 |
51243 |
-197647 |
-308112 |
-6984877 |
-1087711 |
-976924 |
-2529912 |
-1335611 |
| EPS Diluted |
-1747.68 |
-46335 |
51217 |
-197647 |
-308112 |
-6984877 |
-1087711 |
-976924 |
-2529912 |
-1335611 |
| Weighted Average Shares Out |
$13.81 K
|
$375.76
|
$156.64
|
$143.98
|
$104.14
|
$6.40
|
$49.36
|
$46.80
|
$44.40
|
$44.38
|
| Weighted Average Shares Out Diluted |
$13.81 K
|
$375.76
|
$156.72
|
$143.98
|
$104.14
|
$6.40
|
$49.36
|
$46.80
|
$44.40
|
$44.38
|
| Link |
|
|
|
|
|
|
|
|
|
|
